Premium
Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient
Author(s) -
King G. S.,
Cottingham L. G.,
Hughes R. E.,
Ratliff P. D.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12719
Subject(s) - pulmonary embolism , medicine , prothrombin complex concentrate , prothrombin complex , coagulation , warfarin , atrial fibrillation
Summary What is known and objective Prothrombin complex concentrate (PCC) is a plasma‐derived concentrate used to replenish clotting factors. There are limited recommendations for treating coagulopathy induced by direct oral anticoagulants (DOAC). Data are limited regarding both total dose and repeated dosing with this population. Case summary We describe a case of an adult patient anticoagulated with apixaban who received two 35 unit/kg doses of PCC resulting in suspected pulmonary embolism. What is new and conclusion Treatment of DOAC‐induced bleeding remains an “off‐label” indication for PCC. Additional doses should be given with caution if given at all and patients monitored closely.